Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03105687
Other study ID # SPPA-2017
Secondary ID
Status Completed
Phase N/A
First received March 17, 2017
Last updated February 14, 2018
Start date June 16, 2017
Est. completion date February 14, 2018

Study information

Verified date February 2018
Source Comenius University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

By conducting the SPPA trial we try to find out, whether personalized Short Message Service (SMS) reminders of blood pressure-lowering medication can effectively increase patients' adherence to blood pressure-lowering medication. Additionally, we also evaluate their effect on patients' systolic blood pressure control.


Description:

Hypertension belongs to the main risk factors of cardiovascular diseases, which are the leading cause of morbidity and mortality in the world and in the Slovak Republic. Despite the availability of effective antihypertensive treatment, blood pressure control remains a serious problem. Poor adherence to blood pressure-lowering medication is considered to be the key factor for uncontrolled blood pressure. Studies estimate the overall adherence to medication in patients with chronic diseases at around 50%. Slovak studies report even significantly lower adherence rates (15-19%), which underlines the urgency to address this health problem in the Slovak Republic. The majority of interventions aimed at increasing patients' adherence are associated with substantial costs and health care professionals capacity, both lacking in the current Slovak health care system. Several studies have shown the efficiency of SMS reminders to improve patients' adherence and health outcomes at very low cost. Since mobile phones are frequently used among Slovak inhabitants and SMS messages are a popular mean of communication, this approach could be feasible also in Slovakia. Pharmacists are highly trained drug experts who have the knowledge, skills and time to address patients' nonadherence using a simple SMS reminder system.

Thus, our research question is as follows: Do personalized daily SMS reminders of blood pressure-lowering medication intake provided by pharmacists in addition to standard Pharmaceutical Care reduce the proportion of nonadherence to blood pressure-lowering medication among older ambulatory patients with hypertension in Slovakia? And we hypothesize that personalized daily SMS reminders of blood pressure-lowering medication intake provided by pharmacists in addition to standard Pharmaceutical Care increase the proportion of adherence to blood pressure-lowering medication among older ambulatory patients with hypertension in Slovakia from 30% to 49% in the intervention group compared to the control group.


Recruitment information / eligibility

Status Completed
Enrollment 300
Est. completion date February 14, 2018
Est. primary completion date January 10, 2018
Accepts healthy volunteers No
Gender All
Age group 55 Years and older
Eligibility Inclusion Criteria:

- Age = 55 years (from the day of the 55. birthday inclusive)

- Diagnosis of primary (essential) hypertension (I10 according to International Classification of Diseases (ICD-10))

- Filling of blood pressure-lowering prescription(s) at trial recruitment (Visit 1)

- Duration of antihypertensive drug treatment for at least 1 year without any discontinuation

- Ownership of a mobile phone for personal use with the ability to open and read SMS

- Understanding of Slovak language on native-speaker level

- Informed consent for participation in the clinical trial and personally signed Informed Consent Form

Exclusion Criteria:

Exclusion criteria assessed prior to patient enrolment (by trial pharmacists):

- Planned hospitalisation during the trial period (3 months)

- Biological impairment affecting the ability to read the SMS (e.g. loss of vision, visual field cuts, aphasia)

- Living in the same household with another trial participant

- Participation in another clinical trial

Exclusion criteria assessed after patient enrolment (by trial pharmacists and project leader):

- Hospitalisation during the trial period

- Patient informs he/she won't be able to participate in the trial

- Withdrawal of Informed Consent

Study Design


Intervention

Behavioral:
SMS reminders of medicines intake
The intervention consists of daily SMS reminders of blood pressure-lowering medication provided by a pharmacist for a period of 3 months.

Locations

Country Name City State
Slovakia Lekáren Bernolákova, Dr. Max Žilina
Slovakia Lekáren Needham Banská Bystrica
Slovakia Lekáren V KAUFLANDE BB, s.r.o. Banská Bystrica
Slovakia Lekáren DANUBIA Bratislava
Slovakia Lekáren Dr.Max 12 Bratislava
Slovakia Lekáren Poliklinika Šustekova Bratislava
Slovakia Lekáren GREEN-STRAP Dubnica nad Váhom
Slovakia Lekáren Námestie Matice Slovenskej, Dr. Max Dubnica nad Váhom
Slovakia Lekáren Dr.Max 90, Nemocnica s poliklinkou Sv.Lukáša Galanta
Slovakia Lekáren REDMOON Hnúšta
Slovakia Lekáren 17 Kežmarok
Slovakia Lekáren Námestie Osloboditelov, Dr. Max Liptovský Mikuláš
Slovakia Lekáren RED-MARKET s.r.o. Malacky
Slovakia Lekáren PRED NEMOCNICOU Martin
Slovakia Lekáren, OC Tulip Martin
Slovakia Lekáren Námestie Slobody, Dr. Max Pieštany
Slovakia Lekáren HEALTHSTORE Prešov
Slovakia Lekáren Dr.Max 22 Rimavská Sobota
Slovakia Lekáren Dr.Max 36 Rožnava
Slovakia Lekáren OC Madaras Dr. Max Spišská Nová Ves
Slovakia Lekáren EURO FARMÁCIA s.r.o. Trencín
Slovakia Lekáren SD5 s.r.o. Trencín
Slovakia Lekáren CASTILION Vranov nad Toplou
Slovakia Železnicná Lekáren Zvolen

Sponsors (4)

Lead Sponsor Collaborator
Comenius University Dr. Max Pharmacies, Research Institute for Child Psychology and Pathopsychology, University of California, Los Angeles

Country where clinical trial is conducted

Slovakia, 

References & Publications (1)

Haramiova Z, Stasko M, Hulin M, Tesar T, Kuzelova M, Morisky DM. The effectiveness of daily SMS reminders in pharmaceutical care of older adults on improving patients' adherence to antihypertensive medication (SPPA): study protocol for a randomized controlled trial. Trials. 2017 Jul 18;18(1):334. doi: 10.1186/s13063-017-2063-8. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Other Overall direct treatment costs Direct treatment costs (monthly average) of blood pressure-lowering medication for each patient will be assessed according to the List of categorized drugs issued by the Ministry of Health of the Slovak Republic. at Visit 2 (at follow-up visit; 3 months after Visit 1)
Other Signals of adverse events associated with blood pressure-lowering medication During the whole course of the trial we will actively seek for signals of adverse events associated with blood pressure-lowering medication. Patients will have te possibility to report them any time during the trial. Additionally, trial pharmacists will specifically ask the patients about any potential signals of adverse events at Visit 2. at Visit 2 (at follow-up visit; 3 months after Visit 1)
Other Number of patients who refused to participate in the study (Patients Refusal Rate) We will collect the number of patients who refused to participate in the study and report it as percentage of the overall approached patients. Trough enrollment
Other Number of participants who withdrew from the study (Participants Withdrawal Rate) We will collect the number of patients who withdrew from the study (early study termination) and report it as percentage of the overall study participants. Also, anonymous reasons for withdrawal from study will be collected, if the patients wish to provide such information. From date of randomization until Visit 2 (3 months after Visit 1) or the date of early study termination, whichever came first, assessed up to 3 months
Primary Combined adherence endpoint Measurement variable: adherence status (dichotomous) assessed via the eight item Morisky Medication Score (MMAS-8) as follows:
adherent: MMAS-8 score =6 and pill count rate =80% or <=120% non-adherent: MMAS-8 score <6 and/or pill count rate <80% or >120% Analysis Metric: final value (Visit 2) Method of aggregation: proportion of adherent patients (%)
at Visit 2 (follow-up visit after 3 months of intervention period)
Secondary Change in medians of MMAS-8 after 3 months Specific measurement variable: MMAS-8 (categorical, ordinal) Analysis Metric: change from baseline (Visit 1) Method of aggregation: median at Visit 2 (at follow-up visit; 3 months after Visit 1)
Secondary Mean Adherence Rate (%) after 3 months calculated via pill count Specific measurement variable: adherence rate (%), continuous variable Analysis Metric: final value (at Visit 2) Method of aggregation: mean at Visit 2 (at follow-up visit; 3 months after Visit 1)
Secondary Mean change in systolic BP after 3 months Specific measurement variable: systolic blood pressure in mmHg (continuous variable) Analysis Metric:change from baseline (Visit 1) Method of aggregation: mean at Visit 2 (at follow-up visit; 3 months after Visit 1)
Secondary Patients' satisfaction with SMS reminders. Patient satisfaction will be assessed using a Satisfaction Questionnaire based on previous studies. at Visit 2 (at follow-up visit; 3 months after Visit 1)
See also
  Status Clinical Trial Phase
Terminated NCT04591808 - Efficacy and Safety of Atorvastatin + Perindopril Fixed-Dose Combination S05167 in Adult Patients With Arterial Hypertension and Dyslipidemia Phase 3
Recruiting NCT04515303 - Digital Intervention Participation in DASH
Completed NCT05433233 - Effects of Lifestyle Walking on Blood Pressure in Older Adults With Hypertension N/A
Completed NCT05491642 - A Study in Male and Female Participants (After Menopause) With Mild to Moderate High Blood Pressure to Learn How Safe the Study Treatment BAY3283142 is, How it Affects the Body and How it Moves Into, Through and Out of the Body After Taking Single and Multiple Doses Phase 1
Completed NCT03093532 - A Hypertension Emergency Department Intervention Aimed at Decreasing Disparities N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Completed NCT05529147 - The Effects of Medication Induced Blood Pressure Reduction on Cerebral Hemodynamics in Hypertensive Frail Elderly
Recruiting NCT06363097 - Urinary Uromodulin, Dietary Sodium Intake and Ambulatory Blood Pressure in Patients With Chronic Kidney Disease
Recruiting NCT05976230 - Special Drug Use Surveillance of Entresto Tablets (Hypertension)
Completed NCT06008015 - A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1015" and Co-administration of "BR1015-1" and "BR1015-2" Under Fed Conditions in Healthy Volunteers Phase 1
Completed NCT05387174 - Nursing Intervention in Two Risk Factors of the Metabolic Syndrome and Quality of Life in the Climacteric Period N/A
Completed NCT04082585 - Total Health Improvement Program Research Project
Recruiting NCT05121337 - Groceries for Black Residents of Boston to Stop Hypertension Among Adults Without Treated Hypertension N/A
Withdrawn NCT04922424 - Mechanisms and Interventions to Address Cardiovascular Risk of Gender-affirming Hormone Therapy in Trans Men Phase 1
Active, not recruiting NCT05062161 - Sleep Duration and Blood Pressure During Sleep N/A
Not yet recruiting NCT05038774 - Educational Intervention for Hypertension Management N/A
Completed NCT05087290 - LOnger-term Effects of COVID-19 INfection on Blood Vessels And Blood pRessure (LOCHINVAR)
Completed NCT05621694 - Exploring Oxytocin Response to Meditative Movement N/A
Completed NCT05688917 - Green Coffee Effect on Metabolic Syndrome N/A
Recruiting NCT05575453 - OPTIMA-BP: Empowering PaTients in MAnaging Blood Pressure N/A

External Links